Quality of life in chronic obstructive pulmonary disease patients in Russia: results of “IKAR-COPD” multi-center population-based study
https://doi.org/10.18093/0869-0189-2005-0-1-93-102
Abstract
The objective of the “IKAR-COPD” study was to evaluate quality of life in COPD patients with different treatment regimens.
This multi-center population-based study was performed in 10 regions of Russia, 702 COPD patients aged 40 to 85 yrs were included in this study: 18.5 % with COPD stage I, 20.7 % with COPD stage II, 40.9 % with COPD stage III and 19.9 % with COPD stage IV (according to the GOLD 2003 criteria).
The official Russian versions of the MOS SF-36 questionnaire and the St. George’s Respiratory Questionnaire (SGRQ) were used as generic and disease-specific health-related measures of quality of life.
COPD significantly impaired the patients’ quality of life, mostly their physical activity. The quality of life depended on severity of COPD, a patient’s age, duration of the disease and smoking history.
About the Authors
A. G. Chuchalin
НИИ пульмонологии МЗ и СР РФ
Russian Federation
Russian Federation
A. S. Belevsky
НИИ пульмонологии МЗ и СР РФ
Russian Federation
Russian Federation
B. A. Chernyak
Иркутский институт усовершенствования врачей
Russian Federation
Russian Federation
Ya. G. Alexeeva
ГУЗ Отделенческая клиническая больница ст. Волгоград-1
Russian Federation
Russian Federation
I. N. Trofimenko
Иркутский институт усовершенствования врачей
Russian Federation
Russian Federation
A. S. Zaitseva
ГУЗ Отделенческая клиническая больница ст. Волгоград-1
Russian Federation
Russian Federation
References
1. World Health Organization. World health report. Geneva: World Health Organization; 2000.
2. Carrozzi L., Rijcken B., Burney P. et al. Family history for chronic lung diseases and epidemiological determinants of COPD in the three European countries. Eur. Respir. Rev. 2001; 11 (80): 49—54.
3. Lundbäck B., Viegi G., Jönsson E. et al. Bronchitis symptoms in Italy and Sweden — prevalence and risk factors. Eur. Respir. Rev. 2001; 11 (80): 55—64.
4. Nationale Heart, Lung, and Blood Institute. Morbidity & mortality: charbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998. Available from: URL: www.Nhlbi.nih.gov/nhlbi/seiin/other/cht-book/thm.
5. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary desease. The COPD Guidelines Group of the Standards of Care Committee of BTS. Thorax 1997; 52 (suppl. 5): S1—S28.
6. Agusti A.G.N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary desease. Eur. Respir. J. 2003; 21: 347—360.
7. Curtis J.R., Patrick D.L. The assessment of health sta tus among patients with COPD. Eur. Respir. J. 2003; 21 (suppl. 41): 36s—45s.
8. Pauwells R.A., Buist S., Calverley P.M.A. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary desease. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.
9. Ware J.E. SF-36 Health Survey. Manual and interpretation guide. Second printing. Boston, Massachusetts: The Health Institute. New England Medical Center; 1997.
10. Jones P.W., Quirk F.H., Baveystock C.M. The St.George’s respiratory questionnaire. Respir. Med. 1991; 85 (suppl. B): 25—31.
11. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. J.A.M.A. 1994; 272: 1497— 1505.
12. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608—1613.
13. Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomised trial. Am. J. Respir. Crit. Care Med. 2000; 162: 174—178.
14. Чучалина А.Г. (ред.) Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.
15. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819—1823.
16. Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297—1303.
Review
For citations:
Chuchalin A.G., Belevsky A.S., Chernyak B.A., Alexeeva Ya.G., Trofimenko I.N., Zaitseva A.S. Quality of life in chronic obstructive pulmonary disease patients in Russia: results of “IKAR-COPD” multi-center population-based study. PULMONOLOGIYA. 2005;(1):93-102. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-1-93-102
Views:
311
Email this article 